Mortality Outcome of Controlled Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-18

Study Completion Date

2026-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pooled analysis investigates death outcomes in patients with pharmacologically treated and blood pressure-controlled hypertension. Despite documented BP control, some patients still suffer fatal cardiovascular, cerebrovascular, renal, or unexplained syndromes. This study aims to synthesize available evidence across study types to identify treatment pitfalls, contributing syndromes, and non-BP factors associated with these fatal outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Study the Mortality Outcome of Controlled Blood Pressure Participants

NCT07067632

Valid MeSH Conditions Hypertension (HTN)

RECRUITING

Guidelines for Drug Therapy of Hypertension: Closing the Loop

NCT00012636

Hypertension

COMPLETED NA

Observational Study of the Prognosis in Treated Arterial Hypertension

NCT00225030

Hypertension

COMPLETED

The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis

NCT01703780

Hypertension, Resistant to Conventional Therapy

UNKNOWN

Systemic Arterial Hypertension in Pediatric Age.

NCT06797908

Hypertension

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although hypertension is commonly treated and controlled to target levels, fatalities still occur in some patient subgroups. This pooled review seeks to identify and analyze these populations' contributing factors, comorbidities, treatment contexts, and physiological mechanisms associated with mortality. Data will be collected from peer-reviewed studies and registries. Statistical analysis will include descriptive synthesis, subgroup tabulations, and exploratory regression.

Open-label analysis aims to investigate death outcomes among patients with treated and well-controlled hypertension by synthesizing results from published clinical trials, observational studies, and systematic reviews.

The study will statistically evaluate endpoint include fatal cardiovascular, cerebrovascular, renal, or vascular events in patients in any arm with documented blood pressure control, with clearly seen evidence.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Morality Death Pre-Eclampsia Cardiovascular Diseases Stroke Renal Disease Artery Stenosis Arterial Aneurysm Arterial Rupture Maternal Death

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Human studies (RCTs, cohort, case-control, registry studies, etc.) declare participants with treated and controlled hypertension manage (regardless of drug class, duration, or comorbidity) reported mortality outcomes: all-vascular death, cardiovascular death, sudden death, etc.
* Studies in any setting (outpatient, inpatient, long-term follow-up)
* Articles in English
* Full-text available

Exclusion Criteria

* Animal specimen or parameter studies
* Uncontrolled studies (e.g., case series without control, phase I safety trials)
* No mortality endpoint reported
* Purely mechanistic studies or trials that do not address BP or survival directly
* Pediatric studies unless separated subgroup for treated hypertension is available
* Glaucoma or portal hypertension or Pulmonary Hypertension without essential/systemic hypertension outcomes
* Infection without direct declare that septic shock or immunological failure associated by vascular cause from systemic hypertension
* Secondary/post-hoc analyses that do not report original mortality data

Minimum Eligible Age

1 Minute

Maximum Eligible Age

130 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No